Quest Diagnostics and Scipher Medicine, a precision immunology company, announced a multi-pronged collaboration designed to expand patient access to diagnostic services advancing precision medicine for rheumatoid arthritis, or RA. Under a multi-year collaboration, Quest will provide advanced RNA extraction and next-generation sequencing services for Scipher’s PrismRA test. The collaboration centers on Quest’s next-generation sequencing capabilities at its advanced laboratory in Marlborough, Massachusetts. Quest will extract and sequence RNA from PrismRA blood specimens to identify approximately two dozen molecular traits associated with response to TNFi therapies. Through their electronic health record, physicians receive a personalized report with a score indicating predicted response based on analysis of the complete set of laboratory and patient data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics partners with Universal DX for colorectal cancer blood test
- Quest Diagnostics price target raised to $149 from $148 at JPMorgan
- Quest Diagnostics Declares Quarterly Cash Dividend
- Quest Diagnostics management to meet virtually with Oppenheimer
- Quest Diagnostics price target lowered to $140 from $151 at Baird